Literature DB >> 33668899

Synergistic Killing and Re-Sensitization of Pseudomonas aeruginosa to Antibiotics by Phage-Antibiotic Combination Treatment.

Emily Engeman1,2, Helen R Freyberger1,3, Brendan W Corey4, Amanda M Ward1,3, Yunxiu He1,3, Mikeljon P Nikolich1, Andrey A Filippov1,3, Stuart D Tyner1, Anna C Jacobs1,3.   

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa infections pose a serious health threat. Bacteriophage-antibiotic combination therapy is a promising candidate for combating these infections. A 5-phage P. aeruginosa cocktail, PAM2H, was tested in combination with antibiotics (ceftazidime, ciprofloxacin, gentamicin, meropenem) to determine if PAM2H enhances antibiotic activity. Combination treatment in vitro resulted in a significant increase in susceptibility of MDR strains to antibiotics. Treatment with ceftazidime (CAZ), meropenem, gentamicin, or ciprofloxacin in the presence of the phage increased the number of P. aeruginosa strains susceptible to these antibiotics by 63%, 56%, 31%, and 81%, respectively. Additionally, in a mouse dorsal wound model, seven of eight mice treated with a combination of CAZ and PAM2H for three days had no detectable bacteria remaining in their wounds on day 4, while all mice treated with CAZ or PAM2H alone had ~107 colony forming units (CFU) remaining in their wounds. P. aeruginosa recovered from mouse wounds post-treatment showed decreased virulence in a wax worm model, and DNA sequencing indicated that the combination treatment prevented mutations in genes encoding known phage receptors. Treatment with PAM2H in combination with antibiotics resulted in the re-sensitization of P. aeruginosa to antibiotics in vitro and a synergistic reduction in bacterial burden in vivo.

Entities:  

Keywords:  Pseudomonas aeruginosa; antimicrobial resistance; phage therapy; phage–antibiotic synergy; re-sensitization

Year:  2021        PMID: 33668899      PMCID: PMC7996583          DOI: 10.3390/ph14030184

Source DB:  PubMed          Journal:  Pharmaceuticals (Basel)        ISSN: 1424-8247


  46 in total

1.  Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates.

Authors:  Michael Feldgarden; Vyacheslav Brover; Daniel H Haft; Arjun B Prasad; Douglas J Slotta; Igor Tolstoy; Gregory H Tyson; Shaohua Zhao; Chih-Hao Hsu; Patrick F McDermott; Daniel A Tadesse; Cesar Morales; Mustafa Simmons; Glenn Tillman; Jamie Wasilenko; Jason P Folster; William Klimke
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 2.  Clinical relevance of the ESKAPE pathogens.

Authors:  Jack N Pendleton; Sean P Gorman; Brendan F Gilmore
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

Review 3.  Antibiotic discovery: history, methods and perspectives.

Authors:  Guillaume André Durand; Didier Raoult; Grégory Dubourg
Journal:  Int J Antimicrob Agents       Date:  2018-11-23       Impact factor: 5.283

4.  mini-Tn7 insertion in bacteria with single attTn7 sites: example Pseudomonas aeruginosa.

Authors:  Kyoung-Hee Choi; Herbert P Schweizer
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections.

Authors:  Laurent Debarbieux; Dominique Leduc; Damien Maura; Eric Morello; Alexis Criscuolo; Olivier Grossi; Viviane Balloy; Lhousseine Touqui
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

6.  Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii.

Authors:  Madhuri M Sopirala; Julie E Mangino; Wondwossen A Gebreyes; Beth Biller; Tammy Bannerman; Joan-Miquel Balada-Llasat; Preeti Pancholi
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

7.  Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells.

Authors:  Debebe Alemayehu; Pat G Casey; Olivia McAuliffe; Caitriona M Guinane; James G Martin; Fergus Shanahan; Aidan Coffey; R Paul Ross; Colin Hill
Journal:  mBio       Date:  2012-03-06       Impact factor: 7.867

Review 8.  A simple practice guide for dose conversion between animals and human.

Authors:  Anroop B Nair; Shery Jacob
Journal:  J Basic Clin Pharm       Date:  2016-03

Review 9.  Penicillin's Discovery and Antibiotic Resistance: Lessons for the Future?

Authors:  Mariya Lobanovska; Giulia Pilla
Journal:  Yale J Biol Med       Date:  2017-03-29

10.  Phage treatment of an aortic graft infected with Pseudomonas aeruginosa.

Authors:  Benjamin K Chan; Paul E Turner; Samuel Kim; Hamid R Mojibian; John A Elefteriades; Deepak Narayan
Journal:  Evol Med Public Health       Date:  2018-03-08
View more
  8 in total

1.  Synergistic Effects of Bacteriophage vB_Eco4-M7 and Selected Antibiotics on the Biofilm Formed by Shiga Toxin-Producing Escherichia coli.

Authors:  Agnieszka Necel; Sylwia Bloch; Gracja Topka-Bielecka; Agata Janiszewska; Aleksandra Łukasiak; Bożena Nejman-Faleńczyk; Grzegorz Węgrzyn
Journal:  Antibiotics (Basel)       Date:  2022-05-25

2.  Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study.

Authors:  Fernando L Gordillo Altamirano; Xenia Kostoulias; Dinesh Subedi; Denis Korneev; Anton Y Peleg; Jeremy J Barr
Journal:  EBioMedicine       Date:  2022-05-07       Impact factor: 11.205

Review 3.  Phage-Antibiotic Therapy as a Promising Strategy to Combat Multidrug-Resistant Infections and to Enhance Antimicrobial Efficiency.

Authors:  Chengxi Liu; Qixuan Hong; Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Hak-Kim Chan
Journal:  Antibiotics (Basel)       Date:  2022-04-25

4.  Insertion Mutation of MSMEG_0392 Play an Important Role in Resistance of M. smegmatis to Mycobacteriophage SWU1.

Authors:  Zhen Zhang; Zhulan Yang; Junfeng Zhen; Xiaohong Xiang; Pu Liao; Jianping Xie
Journal:  Infect Drug Resist       Date:  2022-02-02       Impact factor: 4.003

Review 5.  Phage therapy of wound-associated infections.

Authors:  Anna Zyman; Andrzej Górski; Ryszard Międzybrodzki
Journal:  Folia Microbiol (Praha)       Date:  2022-01-13       Impact factor: 2.099

Review 6.  Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far.

Authors:  Marzanna Łusiak-Szelachowska; Ryszard Międzybrodzki; Zuzanna Drulis-Kawa; Kathryn Cater; Petar Knežević; Cyprian Winogradow; Karolina Amaro; Ewa Jończyk-Matysiak; Beata Weber-Dąbrowska; Justyna Rękas; Andrzej Górski
Journal:  J Biomed Sci       Date:  2022-03-30       Impact factor: 8.410

7.  Identification and Characterization of vB_PreP_EPr2, a Lytic Bacteriophage of Pan-Drug Resistant Providencia rettgeri.

Authors:  Jaime L Mencke; Yunxiu He; Andrey A Filippov; Mikeljon P Nikolich; Ashton T Belew; Derrick E Fouts; Patrick T McGann; Brett E Swierczewski; Derese Getnet; Damon W Ellison; Katie R Margulieux
Journal:  Viruses       Date:  2022-03-29       Impact factor: 5.818

8.  Preclinical Assessment of Bacteriophage Therapy against Experimental Acinetobacter baumannii Lung Infection.

Authors:  Sandra-Maria Wienhold; Markus C Brack; Geraldine Nouailles; Gopinath Krishnamoorthy; Imke H E Korf; Claudius Seitz; Sarah Wienecke; Kristina Dietert; Corinne Gurtner; Olivia Kershaw; Achim D Gruber; Anton Ross; Holger Ziehr; Manfred Rohde; Jens Neudecker; Jasmin Lienau; Norbert Suttorp; Stefan Hippenstiel; Andreas C Hocke; Christine Rohde; Martin Witzenrath
Journal:  Viruses       Date:  2021-12-24       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.